Aperio Group’s Lifecore Biomedical LFCR Stock Holding History

Aperio Group’s Portfolio LFCR Stock Details LFCR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q3	–	Sell	-973	Closed	-$9K	–	2553
2019 Q2	$9K	Buy	+973	New	+$9.82K	﹤0.01%	2795

Other funds holding LFCR

Wynnefield Capital New York $148M AUM 32.71% 1-Year Est. Return

NIMC

NWQ Investment Management Company Los Angeles, California $2.22B AUM 6.84% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Russell Investments Group London, United Kingdom $93.1B AUM 28.26% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Walthausen & Co Malta, New York $120M AUM 2.66% 1-Year Est. Return

Heartland Advisors Milwaukee, Wisconsin $1.96B AUM 28.26% 1-Year Est. Return

ICOM

Investment Counselors of Maryland Baltimore, Maryland $4.37B AUM 76.25% 1-Year Est. Return

LPAM

Legion Partners Asset Management Los Angeles, California $138M AUM 53.69% 1-Year Est. Return

Aperio Group's LFCR Position: Q3 2019 in Review

Aperio Group sold out of Lifecore Biomedical (LFCR) in Q3 2019, closing a stake of 973 shares — an estimated $9K sold.

Aperio Group first reported a position in LFCR in Q2 2019 and held it in 1 quarter. The position peaked at $9K in Q2 2019. 104 funds tracked by Wall St. Rank hold LFCR as of Q3 2019.

Aperio Group reported no remaining Lifecore Biomedical position as of Q3 2019 after selling out during the quarter.
Aperio Group sold 973 Lifecore Biomedical shares in Q3 2019, an estimated $9K.
Aperio Group first reported a position in Lifecore Biomedical in Q2 2019 and held it in 1 quarter.
Aperio Group's Lifecore Biomedical position peaked at $9K in Q2 2019.
104 funds tracked by Wall St. Rank held Lifecore Biomedical as of Q3 2019.

Based on Aperio Group's 13F filing for Q3 2019, filed 6 Nov 2019.